Endothelial dysfunction in coronary heart disease

Current Opinion in Cardiology

Volumn 11, Issue 4, 1996, Pages 341-350

  McGorisk, Gerard M ^a   Treasure, Charles B ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ARGININE; CALCIUM CHANNEL BLOCKING AGENT; CHOLESTEROL; CYTOKINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIPYRIDAMOLE; FISH OIL; FREE RADICAL; GROWTH FACTOR; HEPARIN; HYDROXYMETHYLGLUTARYL COENZYME A SYNTHASE; LIPID; LOW DENSITY LIPOPROTEIN; NITRIC OXIDE; TICLOPIDINE; WARFARIN;

ARTERY OCCLUSION; ATHEROSCLEROSIS; BLOOD VESSEL WALL; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; ENDOTHELIUM INJURY; HUMAN; INFLAMMATION; ISCHEMIC HEART DISEASE; LIPOPROTEIN METABOLISM; MACROPHAGE; OXIDATION; OXIDATIVE STRESS; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN DEGRADATION; REVIEW; THROMBOCYTE AGGREGATION; THROMBOSIS; VASCULAR ENDOTHELIUM;

CORONARY ARTERIOSCLEROSIS; ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; LIPOPROTEINS, LDL; MALE; OXIDATIVE STRESS;

EID: 0029955130     PISSN: 02684705     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001573-199607000-00002     Document Type: Review

References (109)

1. Vane JR: The Croonian Lecture, 1993. The endothelium: maestro of the blood circulation. Philos Trans R Soc Lond B Biol Sci 1994, 348:225-246.
2. Nakashima M, Feletou M, Vanhoutte PM: Endothelium-dependent hyperpolarization and potassium channels. 1995, (in press).
3. Nakashima M, Mombouli JV, Taylor AA, Vanhoutte PM: Endothelium-dependent hyperpolarization caused by bradykinin in human coronary arteries. J Clin Invest 1993, 92:2867-2871.
4. Anderson TJ, Uehata A, Gerhard MD, Meredith IT, Knab S, Delagrangre, Lieberman EH, Ganz P, Creager MA, Yeung AC, et al.: Close relation of endothelial function in the human coronary artery and peripheral circulations. J Am Coll Cardiol 1995, 26:1235-1241.
5. Celermajer DS, Sorenson KE, Gooch VM, et al.: Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet 1992, 340:1111-1115.
6. Ludmer PL, Selwyn AP, Shook TL, Wayne RR, Mudge GH, Alexander RW, Ganz P: Paradoxical vasoconstriction induced by acetylcholine in atherosclerotic coronary arteries. N Engl J Med 1986, 315:1046-1051.
7. Mintz GS, Painter JA, Pichard AD, Kent KM, et al.: Atherosclerosis in angiographically "normal" coronary artery reference segments: an intravascular ultrasound study with clinical correlations. J Am Coll Cardiol 1995, 25:1479-1485.
8. Lieberman EH, Knab ST, Creager MA: Nitric oxide mediates the vasodilator response to flow in humans [abstract]. Circulation 1994, 90(suppl):1-138.
9. Sorenson KE, Celermajer DS, Spiegelhalter DJ, Georgakapoulos D, Robinson J, Thomas O, Deanfield JE: Non-invasive measurement of human endothelium dependent arterial responses: accuracy and reproducibility. Br Heart J 1995, 74:247-253.
10. Butler J: Shear stress platelet activation. Lancet 1995, 346:841.
11. Schneider DJ, Nordt TK, Sobel BE: Attenuated fibrinolysis and accelerated atherogenesis in type II diabetic patients. Diabetes 1993, 42:1-7.
12. Nordt TK, Sawa H, Fujii S, Sobel BE: Induction of plasminogen activator inhibitor type-1 (PAI-1) by proinsulin and insulin in vivo. Circulation 1995, 91:764-770.
13. Numano F, Kishi Y: Cytotoxic effect of activated platelets on endothelial cells. Intern Med 1995, 34:277-278.
14. Meng YY, Trachtenberg J, Ryan U, Abendschein DR: Potentiation of endogenous nitric oxide with superoxide dismutase inhibits platelet mediated thrombosis in injured and stenotic arteries. J Am Coll Cardiol 1995, 25:269-275.
15. Sawa H, Lundgren C, Sobel BE, Fujii S: Increased intramural expression of plasminogen activator inhibitor type I after balloon injury: a potential progenitor of restenosis. J Am Coll Cardiol 1994, 24:1742-1748.
16. Clarkson P, Montgomery H, Donald A, Powe A, Bull T, Dollery C, Jubb M, World M, Deanfield J: Exercise training enhances endothelial function in young men [abstract]. J Am Coll Cardiol 1996, 27:288A.
17. Plotnick GD, Corretti MC, Vogel RA: Transient impairment of endothelium-dependent brachial artery vasoactivity following a fatty meal [abstract]. J Am Coll Cardiol 1996, 27:287A.
18. Shimokawah H, Aarhus LL, Vanhoutte PM: Porcine coronary arteries with regenerated endothelium have a reduced endothelium-dependent responsiveness to aggregating platelets and serotonin. Circ Res 1989, 64:900-914.
19. Shimokawah H, Vanhoutte PM: Angiographic demonstration of hyperconstriction induced by serotonin and aggregating platelets in porcine coronary arteries with regenerated endothelium. J Am Coll Cardiol 1991, 17:1197-1202.
20. Celermajer DS, Sorensen KE, Spiegelhalter DJ, Georgakopoulos D, Robinson J, Deanfield JE: Aging is associated with endothelial dysfunction in men years before the age related decline in women. J Am Coll Cardiol 1994, 24:471-476.
21. Blumenthal RS, Gloth ST, Reis SE, Heldman AW, Resar JR, Coombs VJ, Gerstenblith G, Brinker JA: Acute administration of estrogen improves coronary vasomotion in men [abstract]. J Am Coll Cardiol 1996, 27:287A.
22. Manolio TA, Furberg CD, Shemanski L, et al.: Associations of postmenopausal estrogen use with cardiovascular disease and its risk factors in older women. Circulation 1993, 88:2163-2171.
23. Gips SJ, Alvarez RJ, Milliken EE, Dang CV, Goldschmidt-Clermont PJ: 17-beta-estradiol inhibits apoptosis of cultured endothelial cells [abstract]. J Am Coll Cardiol 1996, 27:384A.
24. The Writing Group for the PEPI Trial: Effects of estrogens or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The postmenopausal estrogen/progestin interventions (PEPI) trial. JAMA 1995, 273:199-208.
25. Reis SE, Gloth ST, Blumenthal RS, et al.: Ethinyl estradiol acutely attenuates abnormal coronary vasomotor responses. Circulation 1994, 89:52-
26. Cheng LP, Kuhahara M, Jacobsson J, Foegh ML: Inhibition of myointimal hyperplasia and macrophage infiltration by estradiol in aorta allografts. Transplantation 1991, 52:967-972.
27. Chang WC, Nakao J, Orimo H, Murota SI: Stimulation of prostacyclin biosynthetic activity by estradiol in rat aortic smooth muscle cells in culture. Biochim Biophys Acta 1980, 619:107-118.
28. Jiang C, Poole-Wilson PA, Sarrel PM, Mockizuki S, Collins P, Macleod KT: Effect of 17b-oestradiol on contraction, calcium current, and intracellular free calcium in guinea pig isolated cardiac myocytes. Br J Pharmacol 1992, 106:739-745.
29. Rifici VA, Khachadurian AK: The inhibition of low-density lipoprotein oxidation by 17-beta-estradiol. Metabolism 1992, 41:110-1114.
30. Witzum JL: The oxidation hypothesis of atherosclerosis. Lancet 1994, 344:793-795.
31. Chin JH, Azhan S, Hoffman BB: Inactivation of endothelial derived relaxing factor by oxidized lipoproteins. J Clin Invest 1992, 89:10-18.
32. Salonen JT, Yla-Hertuala S, Yamamoto R, Butler S, Korpela H, Salonen R, Nyyssonen K, Palinski W, Witzum JL: Autoantibody against oxidised LDL and progression of carotid atherosclerosis. Lancet 1992, 339:883-887.
33. Karlsson K, Sandstrom J, Edlund A, Edlund T, Marklund SL: Pharmacokinetics of extracellular-superoxide dismutase in the vascular system. Free Radic Biol Med 1993, 14:185-190.
34. Ohara Y, Peterson TE, Harrison DG: Hypercholesterolemia increases endothelial superoxide anion production. J Clin Invest 1993, 91:2546-2451.
35. Babiy AV, Gebicki JM, Sullivan DR: Vitamin E content and low density lipoprotein oxidizability induced by free radicals. Atherosclerosis 1990, 81:175-182.
36. Fayyaz M, Rana M, Kacham S, Padginton C, Sung BH, Wilson MF, Dandona P: Antioxidants are vasodilators [abstract]. J Am Coll Cardiol 1996, 27:130A.
37. Stampfer MJ, Hennekens CH, Manson JE, Colditz GA, Rosner B, Willett WC: Vitamin E consumption and the risk of coronary disease in women. N Engl J Med 1993, 238:1444-1449.
38. Rimm EB, Stampfer MJ, Ascheris A, Giovannucci E, Colditz GA, Willett WC: Vitamin E consumption and the risk of coronary disease in men. N Engl J Med 1993, 238:1450-1456.
39. Hodis HN, Mack WJ, Labree L, et al.: Serial coronary angiographic evidence that antioxidant vitamin intake reduces progression of coronary artery atherosclerosis. JAMA 1995, 273:1849-1854.
40. Stephens NG, Parsons A, Schofield PM, Kelly F, Cheeseman K, Mitchinson MJ, Brown MJ: Randomized controlled trial of vitamin E in patients with coronary disease: Cambridge Heart Antioxidant Study (CHAOS). Lancet 1996, 347:781-786.
41. Timmi FK, Ting HH, Boles KS, Roddy MA, Ganz P, Creager MA: Acute vitamin C administration improves endothelium-dependent vasodilation in insulin dependent diabetic patients [abstract]. J Am Coll Cardiol 1996, 27:177A.
42. Lehr HA, Frei B, Olofsson AM, Carew TE, Arfors KE: Protection from oxidized LDL-induced leukocyte adhesion to microvascular and macrovascular endothelium in vivo by vitamin C but not by vitamin E. Circulation 1995, 91:1525-1532.
43. Salonen JT, Seppanen K, Nyyssonen K, Korpela H, Kauhanen J, Kantola M, Tuomilehto J, Esterbauer H, Tatzber F, Salonen R: Intake of mercury from fish, lipid peroxidation, and the risk of myocardial infarction and coronary, cardiovascular, and any death in eastern Finnish men. Circulation 1995, 91:645-655.
44. Liao F, Andalibi A, Lusis AJ, Fogelman AM: Genetic control of the inflammatory response induced by oxidized lipids. Am J Cardiol 1995, 75:B65-B66.
45. Hackman AM, Abe Y, Insull WE, Pownall H, Smith L, Dunn K, Gotto AM, Ballantyne CM: Levels of soluble cell adhesion molecules in patients with dyslipidemia [abstract]. J Am Coll Cardiol 1996, 27:176A.
46. Marui N, Offerman MK, Swerlick R, Kunsch C, Rosen CA, Ahmad M, Alexander RW, Medford R: Vascular cell adhesion molecule-1 (VCAM-1) gene transcription and expression are regulated through an antioxidant-sensitive mechanism in human vascular endothelial cells. J Clin Invest 1993, 92:1866-1874.
47. Nakai K, Itoh C, Kawozoe K, Miura Y, Sotoyanagi H, Hotta K, Itoh T, Kamata J, Hiramoi K: Concentration of soluble vascular cell adhesion molecules (VCAM-1) correlated with expression of VCAM-1 mRNA in the human atherosclerotic aorta. Coron Artery Dis 1995, 6:497-502.
48. Wang DL, Wung BS, Shyy YJ, Lin CF, Chao YJ, Usami S, Chien S: Mechanical strain induces monocyte chemotactic protein-1 gene expression in endothelial cells. Circ Res 1995, 77:294-302.
49. Zeiher AM, Schray-Utz B, Busse R: Nitric oxide modulates monocyte chemoattractant protein 1 in human endothelial cells: implications for the pathogenesis of atherosclerosis [abstract]. Circulation 1993, 88(suppl I):I-367.
50. Masser PA, Taylor LM, Porter JM: Elevated plasma homocysteine as a risk factor for atherosclerosis. J Irish Coll Phys Surg 1995, 24:25-30.
51. Fryer RH, Wilson BD, Gubler DB, Fitzgerald LA, Rodgers GM: Homocysteine, a risk factor for premature vascular disease and thrombosis, induces tissue factor activity in endothelial cells. Arterioscl Thromb Vasc Biol 1993, 13:1327-1333.
52. Celermajer DS, Sorensen K, Ryalls M, Robinson J, Thomas O, Leonard JV, Deanfield JE: Impaired endothelial function occurs in the systemic arteries of children with homozygous homocystinuria but not in their heterozygous parents. J Am Coll Cardiol 1993, 22:854-858.
53. Pancharuniti N, Lewis CA, Sauberlich HE, et al.: Plasma homocysteine, folate, and vitamin B12 concentrations and risk for early onset coronary artery disease. Am J Clin Nutr 1994, 59:940-948.
54. Clarke R, Daly L, Robinson K, Naughton E, Cahalane S, Fowler B, Graham I: Hyperhomocysteinaemia: an independent risk factor for vascular disease. N Engl J Med 1991, 324:1149-1155.
55. Medrano MJ, Barrado MJ, Almazan J: Is homocysteinemia a risk factor for venous thrombosis and atherosclerotic vascular disease? Lancet 1995, 346:8967:127.
56. Taylor LM, Defrang RD, Harris EJ, Porter JM: The association of elevated plasma homocysteine with progression of symptomatic peripheral arterial disease. J Vasc Surg 1991, 13:128-136.
57. Stampfer MJ, Malinow MR, Willett WC, Newcomer LM, Upson B, Ullman D, Tischler PV, Hennekens CH: A prospective study of plasma homocysteine and risk of cardiac infarction in US physicians. J Am Med Ass 1992, 268:877-881.
58. Jacobsen DW, Gatautis VJ, Green R, et al.: Rapid HPLC determination of total homocysteine and other thiols in serum and plasma: sex differences and correlation with cobalmin and folate levels in healthy subjects. Clin Chem 1994, 40:6:873-881.
59. Tsurumi Y, Nagashima H, Ichikawa KI, Sumiyoshi T, Hosada S: Influence of plasma lipoprotein (a) levels on coronary vasomotor response to acetylcholine. JACC 1995, 26:1242-1250.
60. Sorenson KE, Celermajer DS, Georgakopoulos D, Hatcher G, Betteridge DJ, Deanfield JE: Impairment of endothelium-dependent dilation is an early event in children with familial hypercholesterolemia and is related to the lipoprotein (a) level. J Clin Invest 1993, 93:50-55.
61. Jamieson DG, Usher DC, Rader DJ, Lavi E: Apolipoprotein (a) deposition in atherosclerotic plaques of cerebral vessels. A potential role for endothelial cells in lesion formation. Am J Pathol 1995, 147:1567-1574.
62. Feldman J, Shenker IR, Etzeel RA, et al.: Passive smoking alters lipid profiles in adolescents. Pediatrics 1991, 88:259-264.
63. Zeiher AM, Schachinger V, Minners J: Long term cigarette smoking impairs endothelium-dependent coronary arterial vasodilator function. Circulation 1995, 92:1094-1100.
64. Celermajer DS, Adams MR, Clarkson P, Robinson J, McCredie RI, Donald A, Deanfield JE: Passive smoking and impaired endothelium-dependent arterial dilatation in healthy young adults. N Engl J Med 1996, 334:150-154.
65. Bricio EM, Heilbron RG, Lieberman EH: Effects of acute and chronic cigarette smoking on flow mediated endothelium-dependent vasodilation [abstract]. J Am Coll Cardiol 1996, 27:177A.
66. Celermajer DS, Sorenson KE, Georgakapoulos D, et al.: Cigarette smoking is associated with with dose-related and potentially reversible impairment of endothelium dependent dilation in healthy young adults. Circulation 1993, 88:2149-2155.
67. Rimm EB, Giovannucci EL, Willett WC, et al.: A prospective study of alcohol consumption and risk of coronary disease in men. Lancet 1991, 338:464-468.
68. Reynaud S, De Lorgeril M: Wine, alcohol, platelets, and the French Paradox for coronary heart disease. Lancet 1992, 339:1523-1526.
69. Paunio M, Heinonen OP, Virtamo J, Klag MJ, Manninen V, Albanes D, Comstock GW: HDL cholesterol and mortality in Finnish men with special reference to alcohol intake. Circulation 1994, 90:2909-2918.
70. Suzukawa M, Idshikawa T, Yoshida H, Hosoai K, Nishio E, Yamashita T, Nakamura H, Hashizume N, Suzuki K: Effects of alcohol consumption on antioxidant content and susceptibility of low density lipoprotein to oxidative modification. J Am Coll Nutr 1994, 13:237-242.
71. DeRijke YB, Demacker PNM, Assen NA, Sloots Lm, Katan MB, Stalenhgoef AFH: Red wine consumption and oxidation of low density lipoproteins. Lancet 1995, 345:273-278.
72. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimar AR, Macfarlane PW, Mckillop JH, Packard CJ: Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia (WOSCOPS). N Engl J Med 1995, 333:1302-1307.
73. Engelman DT, Watanabe M, Engelman RM, Rousou JA, Flack JE, Deaton DW: Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994, 344:1383-1389.
74. Scandinavian Simvastatin Survival Study Group: Baseline serum cholesterol and treatment effect in the Scandinavian Simvastatin Survival Study (4S). Lancet 1995, 345:1274-1275.
75. Treasure CB, Klein JL, Weintraub WS, Talley JD, Stillabower BME, Zhang J, Bocuzzi SJ, Kosinski AS, Cedarholm JC, Alexander RW: Beneficial effects of cholesterol lowering therapy on the coronary endothelium in patients with coronary artery disease. N Engl J Med 1995, 332:481-487.
76. Anderson TJ, Meredith IT, Yeumg AC, Frei B, Selwyn AP, Ganz P: The effect of cholesterol-lowering and antioxidant therapy on endothelium dependent coronary vasomotion. N Engl J Med 1995, 332:488-493.
77. Selley ML, Czeti AL, McGuiness JA, Ardlic NG: Dipyridamole inhibits the oxidative modification of low density lipoprotein. Atherosclerosis 1994, III:19-97.
78. Keaney JF, Xu A, Cunningham DC, Jackson T, Frei B, Vita JA: Dietary probucol preserves endothelial function in cholesterol fed rabbits by limiting vascular oxidative stress and superoxide production. J Clin Invest 1995, 95:2520-2529.
79. Brown SL, Sobel BE: Attenuation of the synthesis of plasminogen activator inhibitor type-1 by niacin. A potential link between lipid lowering and fibrinolysis. Circulation 1995, 92:767-772.
80. Fujii S, Sawa H, Sobel BE: Inhibition of endothelial expression of plasminogen activator inhibitor type-1 by gemfibrizil. Thromb Haemost 1993, 70:642-647.
81. Kromhout D, Bosschieter EB, de Lezenne Coulander C: The inverse relation between fish consumption and 20-year mortality from coronary heart disease. N Engl J Med 1985, 312:1205-1209.
82. Norell SE, Ahlbom A, Feychting M, Pedersen NL: Fish consumption and mortality from coronary heart disease. BMJ 1986, 293:426.
83. Shekelle RB, Missell LV, Paul O, Shyrock AM, Stamler J: Fish consumption and mortality from coronary heart disease. N Engl J Med 1985, 313:820.
84. Vollset SE, Heuch I, Bjelke E: Fish consumption and mortality from coronary heart disease. N Engl J Med 1985, 313:820-821.
85. Leaf A, Weber PC: Cardiovascular effects of n-3 fatty acids. N Engl J Med 1988, 318:549-557.
86. Schmidt EB, Dyerberg J: Omega-3 fatty acids: current status in cardiovascular medicine. Drugs 1994, 47:405-424.
87. Hirai A, Hamazaki T, Terano T, et al.: Eicosapentaenoic acid and platelet function in Japanese. Lancet 1980, 2:1132-1133.
88. Kim DN, Eastman A, Baker JE, Mastrangelo A, Sethi S, Ross JS, Schmee J, Thomas WA: Fish oil, atherogenesis, and thrombogenesis. Ann N Y Acad Sci 1995, 748:474-480.
89. Ascherio A, Rimm EB, Stampfer MJ, Giovannucci EL, Willet WC: Dietary intake of marine n-3 fatty acids, fish intake, and the risk of coronary disease among men. N Engl J Med 1995, 332:977-982.
90. Cooke JP, Singer AH, Tsao P, Zera P, Rowan RA, Billingham ME: Antiatherogenic effects of L-arginine in the hypercholesterolemic rabbit. Journal of Clinical Investigation 1992, 90:1168-1172.
91. Adams MR, Forsyth CJ, Jessup W, Robinson J, Celermajer DS: Oral L-arginine inhibits platelet aggregation but does not enhance endothelium-dependent dilation in healthy young men. J Am Coll Cardiol 1995, 26:1054-1061.
92. Davies MG, Dalen H, Kim JH, Barber L, Svendson, Hagen PO: L-arginine control of accelerated vein graft atheroma with the nitric oxide precursor L-arginine. J Surg Res 1995, 59:35-42.
93. Vanhoutte PM, Boulanger CM, Mombouli JV: Endothelium-derived relaxing factors and converting enzyme inhibition. Am J Cardiol 1995, 76:3E-12E.
94. Drexler H, Kurz S, Jeserich M, Munzel T, Hornig B: Effect of chronic angiotensin-converting enzyme inhibition on endothelial function in patients with chronic heart failure. Am J Cardiol 1995, 76:13E-18E.
95. Croft KD, Dimmitt SB, Moulton C, Beilin LT: Low density lipoprotein composition and oxidizability in coronary disease-apparent favourable effect of beta blockers. Atherosclerosis 1992, 97:123-130.
96. Yue TL, McKenna PJ, Lysko PG, GU JL, Lysko KA, Ruffolo RR, Feuerstein GZ: SB 211475, a metabolite of carvedilol, a novel antihypertensive agent, is a potent antioxidant. Eur J Pharmacol 1994, 251:237-243.
97. Mak IT, Boehme P, Weglicki WB: Protective effects of calcium blockers against free-radical impaired endothelial cell proliferation. Biochem Pharmacol 1995, 50:1531-1534.
98. Waters D, Lesperance J: Calcium channel blockers and coronary atherosclerosis: from the rabbit to the real world. Am Heart J 1994, 128:1309-1316.
99. Lacoste LL, Lam JYT, Hung J, Waters D: Oral verapamil inhibits platelet thrombus formation in in men. Circulation 1994, 89:630-634.
100. Tuliano L, Pedersen JZ, Rptilio G, Ferro D, Violi F: A potent chain-breaking antioxidant activity of the cardiovascular drug dipyridamole. Free Radic Biol Med 1995, 18:239-247.
101. Johnston TJ, Harrison DG, Klein JL, Anderson WD, Marshall JJ, Zhang J, Alexander RW, Treasure CB: Xanthine oxidase inhibition improves coronary endothelium mediated relaxation in patients with early atherosclerosis [abstract]. J Am Coll Cardiol 1995, 26:115A.
102. Berman RS, Martin WE: Arterial endothelial barrier dysfunction: actions of homocysteine and the hypoxanthine-xanthine oxidase free radical generating system. Br J Pharmacol 1993, 108:920-926.
103. Gordon BR, Saal SD: Advances in LDL apheresis for the treatment of severe hypercholesterolemia. Curr Opin Lipidol 1994, 5:69-73.
104. Nathan A, Nugent MA, Edelman ER: Tissue engineered perivascular endothelial cell implants regulate vascular injury. Proc Natl Acad Sci U S A 1995, 92:8130-8134.
105. Feldman LJ, Isner JM: Gene therapy for the vulnerable plaque. J Am Coll Cardiol 1995, 26:826-835.
106. Sawa H, Sobel BE, Fujii S: Inhibition of type-I plasminogen activator inhibitor production by antisense oligonucleotides in human vascular endothelial and smooth muscle cells. J Biol Chem 1994, 269:14149.
107. Asahara T, Bauters C, Pastore C, et al.: Local delivery of vascular endothelial growth factor accelerates reendothelialization and attenuates intimal hyperplasia in ballon injured rat carotid artery. Circulation 1995, 91:2793-2801.
108. Asahara T, Bauters C, Wu T, Zheng LP, Chen D, Kearney M, Rossow S, Bunting S, Ferrara N, Symes JF, et al.: Restoration of endothelial function in hypercholesterolemic rabbit by intermittent administration of vascular endothelial growth factor [abstract]. J Am Coll Cardiol 1995, 366A.
109. Offermann MK, Meaford RM: Antioxidants and atherosclerosis: a molecular perspective. Heart Dis Stroke 1994, 3:52-57.